Drugs and drug delivery strategies for treatment of pulmonary arterial hypertension
10.16438/j.0513-4870.2020-1896
- VernacularTitle:肺动脉高压的药物治疗及药物递送策略
- Author:
Xiao-hong JIANG
;
Xu-yang XING
;
Xiao-chun WANG
;
Li-fang YIN
;
Wei HE
- Publication Type:Research Article
- Keywords:
pharmaceutics;
pulmonary arterial hypertension;
rug delivery;
therapy
- From:
Acta Pharmaceutica Sinica
2021;56(5):1332-1342
- CountryChina
- Language:Chinese
-
Abstract:
Pulmonary arterial hypertension (PAH), also named as a cancer of cardiovascular disease, is a rare disease and has complicated pathogenesis. Recently, there are more understandings of PAH pathogeneses. According to the pathogenesis and active pathways, the clinically used drugs are classified into several groups incluidng prostacyclin analogues and prostacyclin receptor agonists, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase inhibitors, etc. To elevate the efficacy of the drugs, numerous drug delivery systems are developed. This review mainly summarized the pathological mechanism of PAH, drugs and drug delivery approaches in the treatment of PAH.
